GSA Capital Partners’s Albany Molecular Research Inc AMRI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q3 | – | Sell |
-24,670
| Closed | -$535K | – | 2046 |
|
|
2017
Q2 | $535K | Sell |
24,670
-58,136
| -70% | -$1.06M | 0.03% | 972 |
|
|
2017
Q1 | $1.16M | Buy |
82,806
+51,300
| +163% | +$840K | 0.06% | 544 |
|
|
2016
Q4 | $591K | Buy |
31,506
+17,607
| +127% | +$299K | 0.04% | 887 |
|
|
2016
Q3 | $229K | Sell |
13,899
-56,228
| -80% | -$833K | 0.01% | 1533 |
|
|
2016
Q2 | $943K | Sell |
70,127
-120,560
| -63% | -$1.76M | 0.05% | 672 |
|
|
2016
Q1 | $2.92M | Buy |
190,687
+75,940
| +66% | +$1.19M | 0.19% | 72 |
|
|
2015
Q4 | $2.28M | Sell |
114,747
-14,508
| -11% | -$276K | 0.11% | 207 |
|
|
2015
Q3 | $2.25M | Sell |
129,255
-18,700
| -13% | -$381K | 0.11% | 215 |
|
|
2015
Q2 | $2.99M | Buy |
147,955
+34,383
| +30% | +$664K | 0.11% | 179 |
|
|
2015
Q1 | $2M | Buy |
113,572
+58,112
| +105% | +$990K | 0.08% | 346 |
|
|
2014
Q4 | $903K | Buy |
55,460
+7,271
| +15% | +$133K | 0.06% | 537 |
|
|
2014
Q3 | $1.06M | Buy |
+48,189
| New | +$987K | 0.06% | 444 |
|
|
2014
Q2 | – | Sell |
-40,903
| Closed | -$760K | – | 2059 |
|
|
2014
Q1 | $760K | Sell |
40,903
-78,111
| -66% | -$1.08M | 0.05% | 482 |
|
|
2013
Q4 | $1.2M | Buy |
119,014
+7,545
| +7% | +$91.2K | 0.09% | 268 |
|
|
2013
Q3 | $1.44M | Buy |
111,469
+35,855
| +47% | +$441K | 0.11% | 194 |
|
|
2013
Q2 | $898K | Buy |
+75,614
| New | +$819K | 0.11% | 251 |
|
Other funds holding AMRI
GSA Capital Partners's AMRI Position: Q3 2017 in Review
GSA Capital Partners sold out of Albany Molecular Research Inc (AMRI) in Q3 2017, closing a stake of 24,670 shares — an estimated $535K sold.
GSA Capital Partners first reported a position in AMRI in Q2 2013 and held it in 16 quarters. The position peaked at $2.99M in Q2 2015. 2 funds tracked by Wall St. Rank hold AMRI as of Q3 2017.
- GSA Capital Partners reported no remaining Albany Molecular Research Inc position as of Q3 2017 after selling out during the quarter.
- GSA Capital Partners sold 24,670 Albany Molecular Research Inc shares in Q3 2017, an estimated $535K.
- GSA Capital Partners first reported a position in Albany Molecular Research Inc in Q2 2013 and held it in 16 quarters.
- GSA Capital Partners's Albany Molecular Research Inc position peaked at $2.99M in Q2 2015.
- 2 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2017.
Based on GSA Capital Partners's 13F filing for Q3 2017, filed 20 Nov 2017.